摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(5-bomo-2-chloro-3-hydroxyphenyl)(phenyl)methanone

中文名称
——
中文别名
——
英文名称
(5-bomo-2-chloro-3-hydroxyphenyl)(phenyl)methanone
英文别名
(5-bromo-2-chloro-3-hydroxyphenyl)(phenyl)methanone;(5-Bromo-2-chloro-3-hydroxyphenyl)(phenyl)methanone;(5-bromo-2-chloro-3-hydroxyphenyl)-phenylmethanone
(5-bomo-2-chloro-3-hydroxyphenyl)(phenyl)methanone化学式
CAS
——
化学式
C13H8BrClO2
mdl
——
分子量
311.562
InChiKey
DSECKFPDMHVHEY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] METHOD FOR PRODUCING DIPHENYLMETHANE DERIVATIVE<br/>[FR] PROCÉDÉ DE PRODUCTION D'UN DÉRIVÉ DE DIPHÉNYLMÉTHANE<br/>[KO] 다이페닐메탄 유도체의 제조방법
    申请人:DAE WOONG PHARMA
    公开号:WO2017217792A1
    公开(公告)日:2017-12-21
    본 발명은 나트륨-의존성 글루코스 공수송체(SGLT)의 억제제로서 유용한 다이페닐메탄 유도체를 제조하는 개선된 방법에 관한 것으로서, 주요 그룹별로 개별적으로 합성한 뒤 커플링시키는 수렴 합성(convergent synthesis) 방식으로 수행되므로, 종래문헌에 개시된 순차 합성(linear synthesis) 방식에 비해 합성 경로가 간결하고 수율을 높일 수 있으며, 순차 합성 경로가 내재하고 있는 위험요소를 줄일 수 있다. 또한, 상기 방법에 의해 제조된 화합물의 결정형은 물리화학적 특성이 우수하여, 약제 제조 등의 분야에서 유용하게 활용될 수 있다.
    本发明涉及一种改进的方法,用于制备对钠依赖性葡萄糖共运输体(SGLT)具有抑制作用的有用二苯甲烷衍生物。该方法采用汇合合成法,即先分别合成主要基团,然后将它们耦合,与传统文献中的线性合成法相比,合成路径更为简洁,可以提高收率,并降低线性合成路径所固有的风险因素。此外,通过该方法制备的化合物的晶体形态具有优异的物理化学特性,可在药物制造等领域中得到有益利用。
  • NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS
    申请人:Choi Soongyu
    公开号:US20140088079A1
    公开(公告)日:2014-03-27
    The present invention relates to a compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The present invention also provides a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound.
    本发明涉及一种具有二苯甲烷基团的化合物,其具有对存在于肠和肾中的钠依赖性葡萄糖共转运体2(SGLT2)的抑制活性,以及包含该化合物作为活性成分的制药组合物,用于预防或治疗代谢性疾病,尤其是糖尿病。本发明还提供了一种制备该化合物的方法,以及使用该化合物预防或治疗代谢性疾病,尤其是糖尿病的方法。
  • Diphenylmethane derivatives as SGLT2 inhibitors
    申请人:GREEN CROSS CORPORATION
    公开号:US09371303B2
    公开(公告)日:2016-06-21
    A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.
    本发明揭示了一种含有二苯甲烷基团的化合物,该化合物具有抑制存在于肠和肾中的钠依赖性葡萄糖共转运体2(SGLT2)的活性。本发明还揭示了一种包括该化合物作为活性成分的制药组合物,该组合物可用于预防或治疗代谢紊乱,特别是糖尿病。本发明还提供了一种制备该化合物的方法,以及使用该化合物预防或治疗代谢紊乱,特别是糖尿病的方法。
  • DIPHENYLMETHANE DERIVATIVE IN CRYSTALLINE FORM
    申请人:Daewoong Pharmaceutical Co., Ltd.
    公开号:EP3663292A1
    公开(公告)日:2020-06-10
    The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.
    本发明涉及一种生产作为钠依赖性葡萄糖共转运体(SGLT)抑制剂有效的二苯基甲烷衍生物的改进方法,该方法通过聚合合成法进行,其中每个主要基团分别合成,然后偶联。因此,与现有文献中公开的线性合成方法相比,合成途径紧凑,产量可以提高,并且可以减少线性合成途径中固有的风险因素。此外,根据该方法制得的化合物晶体具有极佳的理化特性,因此可有效地用于制药等领域。
  • Method for producing diphenylmethane derivative
    申请人:DAEWOONG PHARMACEUTICAL CO., LTD.
    公开号:US10640496B2
    公开(公告)日:2020-05-05
    The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.
    本发明涉及一种生产作为钠依赖性葡萄糖共转运体(SGLT)抑制剂有效的二苯基甲烷衍生物的改进方法,该方法通过聚合合成法进行,其中每个主要基团分别合成,然后偶联。因此,与现有文献中公开的线性合成方法相比,合成途径紧凑,产量可以提高,并且可以减少线性合成途径中固有的风险因素。此外,根据该方法制得的化合物晶体具有极佳的理化特性,因此可有效地用于制药等领域。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐